Records containing: Influenza, Human
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2013-05-07Safety and Immunogenicity of a Second Vaccination With GSK Biologicals' Influenza Vaccine GSK1247446A in Subjects 18-60 Years Previously Vaccinated in Study 108656
-
CLINICAL_TRIALS study record update · 2012-05-21Tolerability and Immunogenicity Study of FLUVAL P H1N1 Monovalent Influenza Vaccine of Omninvest in Children and Adolescents
-
CLINICAL_TRIALS study record update · 2012-04-02Phase 1 Study of TCN-032 (Human Monoclonal Antibody Directed Against the M2 Protein of Influenza A Virus) in Healthy Adult Volunteers
-
CLINICAL_TRIALS study record update · 2011-11-22A Randomized Double-blind Controlled Study of CS-8958 Versus Oseltamivir Phosphate in Patients With Influenza Virus Infection
-
CLINICAL_TRIALS study record update · 2011-10-17A Prospective, Observational Safety Study in Children <= 24 Months of Age Receiving Oseltamivir for the Treatment or Prophylaxis of Influenza Infection
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2011-04-12Collection of Patients' Background InformationRelenza® Sentinel Site Monitoring Program in Japan
-
CLINICAL_TRIALS study record update · 2011-03-04Prophylactic Efficacy of Relenza Against Influenza A and B
-
CLINICAL_TRIALS study record update · 2011-01-05Randomised, Double-blind, Placebo-controlled, Phase IIa Dose Finding Study of Single Dose GHB11L1 in Healthy Adults
-
CLINICAL_TRIALS study record update · 2010-08-13Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years.